Hospitals will no longer need to report influenza data and inventory and usage data for bamlanivimab administered alone as part of their daily data reporting related to COVID-19 effective June 10, when reporting data for those fields will become optional, the Department of Health and Human Services announced last month. Hospitals can upload templates without any change. HHS expects to update its web application early next week.
 
The Food and Drug Administration recently revoked its emergency use authorization for bamlanivimab when administered alone, which prompted HHS to make those fields optional. The influenza data fields may become mandatory again after Oct. 1, when acute respiratory illnesses are likely to increase, HHS said.
 
Reporting COVID-19-related data is a condition of participation for hospitals that participate in Medicare. “We are also working closely with CMS, and any entities who would prefer to implement the changes before June 10 are welcome to do so without any penalties,” HHS said. “States that are certified to submit on behalf of their hospitals will make the appropriate changes and communicate any updates to you. Please follow your state guidance on how and when to update your reporting.”

 

Related News Articles

Headline
The Department of Health and Human Services today announced a $3 billion investment in antiviral treatments for COVID-19, particularly those administered…
Headline
The AHA yesterday joined the U.S. Chamber of Commerce and other national organizations in urging the 9th Circuit Court of Appeals to affirm a district court…
Headline
The Centers for Disease Control and Prevention June 11 updated requirements for health care providers participating in the COVID-19 Vaccination Program to…
Headline
A National Institutes of Health-led review of more than 24,000 stored blood samples suggests that the coronavirus that causes COVID-19 was present in the…
Headline
The Food and Drug Administration yesterday authorized for emergency use one more batch of drug substance manufactured for the Janssen (Johnson &…
Headline
Rhode Island health care providers may no longer order the monoclonal antibodies bamlanivimab and etesevimab until further notice due to rising prevalence of…